Evidence map›Paper›PMID 25312738›Full record

ReviewCurrent pharmaceutical design2015

Modular nanotransporters for targeted intracellular delivery of drugs: folate receptors as potential targets.

Tatiana A Slastnikova, Andrey A Rosenkranz, Michael R Zalutsky, Alexander S Sobolev

Abstract readReview
In one paragraph

Review in Current pharmaceutical design, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.9field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 22 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Antitumor efficacy of Auger electron emitterDoklady. Biochemistry and biophysics · 2017
    Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Tatiana A Slastnikova
Andrey A Rosenkranz
Michael R Zalutsky
Alexander S SobolevLaboratory for Molecular Genetics of Intracellular Transport, Institute of Gene Biology, Russian Academy of Sciences, 34/5 Vavilov St., Moscow, 119334, Russia. sobolev@igb.ac.ru.
Institute of Gene Biology · RU

Funding

TUMOR SUPPRESSOR GENES IN HUMAN MEDULLOBLASTOMAP50NS020023 · NINDS · DUKE UNIVERSITY · PI ZALUTSKY, MICHAEL ROD · 1985 to 2013
$17.3M
RADIOTHERAPY USING MONOCLONAL ANTIBODIES AND ASTATINER01CA042324 · NCI · DUKE UNIVERSITY · PI ZALUTSKY, MICHAEL ROD · 1985 to 2020
$4.6M
NCI NIH HHS R01 CA042324NINDS NIH HHS NS20023NINDS NIH HHS P50 NS020023
6 · The paper itself

Abstract

The review is devoted to a subcellular drug delivery system, modular nanotransporters (MNT) that can penetrate into target cells and deliver a therapeutic into their subcellular compartments, particularly into the nucleus. The therapeutics which need such type of delivery belong to two groups: (i) those that exert their effect only when delivered into a certain cell compartment (like DNA delivered into the nucleus); and (ii) those drugs that are capable of exerting their effect in different parts of the cells, however there can be found a cell compartment that is the most sensitive to their effect. A particular interest attract such cytotoxic agents as Auger electron emitters which are known to be ineffective outside the cell nucleus, whereas they possess high cytotoxicity in the vicinity of nuclear DNA through the induction of non-reparable double-strand DNA breaks. The review discusses main approaches permitting to choose internalizable receptors permitting both recognition of target cells and penetration into them. Special interest attract folate receptors which become accessible to blood circulating therapeutics after malignant transformation or on activated macrophages which makes them an attractive target for both several oncological and inflammatory diseases, like atherosclerosis. In vitro and in vivo experiments demonstrated that MNT is a promising platform for targeted delivery of different therapeutics into the nuclei of target cells.

Indexed as

Molecular Targeted TherapyNanotechnologyAnti-Inflammatory AgentsAtherosclerosisDrug Delivery SystemsEndocytosisFolate Receptors, GPI-AnchoredHumansModels, BiologicalAnti-Inflammatory AgentsFolate Receptors, GPI-Anchored

Identifiers

PMID25312738
PMCPMC4447331
OpenAlexW2161237632

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.